1. Home
  2. HHS vs MRKR Comparison

HHS vs MRKR Comparison

Compare HHS & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harte-Hanks Inc.

HHS

Harte-Hanks Inc.

N/A

Current Price

$4.52

Market Cap

17.7M

ML Signal

N/A

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

N/A

Current Price

$1.04

Market Cap

19.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HHS
MRKR
Founded
1923
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.7M
19.5M
IPO Year
1994
2010

Fundamental Metrics

Financial Performance
Metric
HHS
MRKR
Price
$4.52
$1.04
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $7.87
AVG Volume (30 Days)
★ 94.9K
64.1K
Earning Date
11-09-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 97.35
33.61
EPS
N/A
★ N/A
Revenue
★ $159,570,000.00
N/A
Revenue This Year
N/A
$19.61
Revenue Next Year
N/A
$375.85
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$2.00
$0.84
52 Week High
$4.67
$2.46

Technical Indicators

Market Signals
Indicator
HHS
MRKR
Relative Strength Index (RSI) 65.97 37.42
Support Level $4.14 $1.08
Resistance Level N/A $1.31
Average True Range (ATR) 0.09 0.07
MACD -0.05 -0.01
Stochastic Oscillator 74.42 4.17

Price Performance

Historical Comparison
HHS
MRKR

About HHS Harte-Hanks Inc.

Harte-Hanks Inc is a customer experience company. The company operates three business segments: Revenue Solutions; Customer Care; and Fulfillment & Logistics Services. It derives maximum revenue from Fulfillment & Logistics Services segment. The Fulfillment & Logistics Services segment includes printing, lettershop, advanced mail optimization (including commingling services), logistics and transportation optimization, monitoring and tracking, to support traditional and specialized mailings. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Share on Social Networks: